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SUMMARY— Twenty-four–hour
ambulatory blood pressure monitoring
(ABPM) is a method widely used in hy-
pertension diagnosis and management.
Alsoindiabeticsubjects,itmaybeapow-
erful tool for a better stratiﬁcation of car-
diovascular risk related to elevated blood
pressure (BP), one of the most important
causes of morbidity and mortality in this
population. This is due to its capacity, as
compared with isolated ofﬁce measure-
ments, to more precisely diagnose and
quantify a high BP condition in daily life
and to detect alterations of 24-h BP pro-
ﬁles such as absence of nocturnal BP fall,
postprandial hypotension, or an in-
creasedBPvariability,whichmayreﬂecta
deranged cardiovascular regulation often
associated with a reduced heart rate vari-
ability. It is also an important tool to ob-
tain an accurate assessment of the efﬁcacy
of antihypertensive treatment over day
andnight.Admittedly,thismethodhasits
disadvantages, which include relatively
high cost, problems with validation of the
devices (particularly relevant in special
populations such as diabetic patients),
and undeﬁned diagnostic threshold in
high-risk populations. A number of stud-
ieshaveshownthatABPMmaybeauseful
tool in improving outcome and quality of
life in diabetes, suggesting that it should
be an integral part of the clinical manage-
ment in this setting. However, due to its
limited availability in clinical practice, it
maynotbeeasilyappliedineverydiabetic
subject and thus priority should be given
to those of diabetic patients, who may de-
rive the most evident beneﬁts from the
use of this diagnostic tool.
INTRODUCTION— The24-hABPM
is a method widely used in hypertension
diagnosis and management (1–3). Numer-
ous studies over the years have conﬁrmed
its advantages over the traditional clinic
measurement,includingahigherreproduc-
ibility,lackofplaceboandwhitecoateffect,
and, most importantly, its superiority in
predicting adverse consequences of hyper-
tension. Additionally, ABPM provides an
insight into the features of 24-h BP variabil-
ity, which cannot be assessed with either
clinic or home BP measurement (1–3).
An accurate diagnosis of hyperten-
sion and a reliable assessment of its con-
trolareofuppermostimportanceinhigh-
risk subjects, in whom each mmHg of BP
reduction translates into an important re-
duction of hypertension-related morbid-
ity and mortality (1,4). Diabetes is widely
recognizedtobeaconditionleadingtoan
importantelevationofcardiovascularrisk
in combination with hypertension, this
being relevant both in individual patients
and in terms of public health. Indeed,
missed hypertension diagnosis or inade-
quate control of BP levels in diabetic sub-
jects are common (5).
A number of diagnostic and thera-
peutic tools are available to improve this
situation, and ABPM is one of them. In-
terestingly, the usefulness of ABPM in di-
abetesisrelatednotonlytothepossibility
of assessing the features of BP elevation
over 24 h, but also to its ability to identify
BP patterns reﬂecting an important
pathophysiological mechanism underly-
ing the cardiovascular effects of diabetes,
namely autonomic dysfunction.
This article is aimed at discussing the
evidence supporting use of ABPM in pa-
tients with diabetes and, based on this ev-
idence, at suggesting the possible clinical
indications for ABPM in individual dia-
betic patients.
EVIDENCE ON ABPM
USEFULNESS IN
DIABETES— All the methodological
advantagesofABPM,comparedwithcon-
ventional isolated ofﬁce BP readings, are
fully evident in diabetic subjects, in
whom this method, which is operator in-
dependent, offers important information
relatedtothelargenumberofBPreadings
provided,toitsabilitytoofferinsightinto
24-hBPproﬁles(includingnighttimeand
morning BP values) and to the possibility
to quantify BP variability over the whole
24-h period (2,3). Some studies have
shownthatreproducibilityofBPvaluesin
diabetic subjects is probably better with
ABPM than with clinic BP (6). Moreover,
other favorable features of ABPM, previ-
ouslydemonstratedinuncomplicatedhy-
pertensive subjects, also characterize its
application in the diagnostic and thera-
peutic management of diabetic subjects
with hypertension. These include the ab-
sence of a white-coat effect (i.e., the in-
crease in BP triggered by an emotional
reaction to its measurement in the physi-
cian’s ofﬁce) and of a placebo effect when
assessing response to antihypertensive
treatment (2,3).
The above methodological advan-
tages were clearly shown to importantly
contribute to the higher predictive value
ofABPMintheprognosticstratiﬁcationof
hypertensive patients. Similarly, as in a
nondiabetic population, out-of-ofﬁce BP
values obtained through ABPM in pa-
tients with diabetes were found to corre-
late better than ofﬁce BP with organ (in
particularrenal)damage(7,8)andcardio-
vascular events (9).
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HYPERTENSION— An important
issue related to the parallel use of ofﬁce
and out-of-ofﬁce BP measurement meth-
ods (the latter including also home BP
monitoring) in the same subjects when
diagnosing hypertension or when assess-
ing its coverage by treatment should be
mentioned in this context. It has been re-
ported that, in a signiﬁcant proportion of
subjects, major differences occur in the
deﬁnitionofBPlevelsobtainedwiththese
different approaches to BP measurement.
In a general population, the diagnosis of
hypertension based on elevated ofﬁce BP
values is not conﬁrmed by out-of-ofﬁce
measurements in 20% of subjects, in
whom normal values are found at home
or over the 24 h (a condition deﬁned as
white-coat hypertension) (10,11). Con-
versely, in another 10–20% of subjects,
the opposite situation is found, namely,
an elevation in daily life BP identiﬁed by
either ABPM or home BP monitoring re-
mains undiagnosed during the clinic or
ofﬁce visit (a condition indicated as
maskedhypertension)(11).Theprognos-
tic signiﬁcance of white-coat hyperten-
sion is uncertain, with these subjects
probably being at an intermediate risk
level between normotensives and sus-
tained hypertensives (10,11). On the
otherhand,anumberofstudieshavecon-
sistently shown that masked hyperten-
sion is associated with an elevated
cardiovascular risk, similar to that of sus-
tained hypertension (11).
The data on white-coat hypertension
andmaskedhypertensionindiabeticsub-
jects are rather limited. The available in-
formation is largely in line with the data
obtained in nondiabetic subjects, al-
though some differences should be un-
derlined. There is evidence, for instance,
that the prevalence of white-coat hyper-
tension in this population may be lower
than in a general population, in particu-
lar,whensubjectswithdiabeticnephrop-
athy are concerned (12). This should not
be surprising given that these subjects
tend to have sustained and marked BP el-
evation,whereaswhite-coathypertension
is most common in subjects with BP close
to the threshold for hypertension diagno-
sis. On the other hand, it was suggested
thatmaskedhypertensionmaybepresent
in one out of two subjects with type 2
diabetes and apparently normal clinic BP
(13). High prevalence of masked hyper-
tension becomes particularly relevant
whenweconsiderthatthisconditionmay
beassociatedwithhigherriskofbrainand
kidney damage (14,15) and possibly also
of cardiac damage (13), which further in-
creases the already very high risk of car-
diovascular complications typical of
diabetic subjects. As far as white-coat hy-
pertension is concerned, it appears to be
associated with a lower risk than sus-
tained hypertension also in a diabetic
population (16).
ASSESSMENT OF 24-H BP
PROFILES— One application of
ABPM in diabetic subjects that has raised
particular interest is the possibility to de-
tect the alterations of day-night BP
changes that often characterize such a
pathological condition. Speciﬁcally, a
lack of nocturnal BP fall (nondipping) or
even an increase of BP during the night
(reverse dipping) is common in this pop-
ulation, with its prevalence reaching
30% (17,18) (Fig. 1). It was suggested
that these conditions may reﬂect auto-
nomic dysfunction (19), and some au-
thors suggest that they might be used as a
clinical marker of diabetic autonomic
neuropathy (20). However, it has to be
remembered that other pathophysiologi-
cal mechanisms may also be involved. In
particular, obstructive sleep apnea, com-
monly encountered in obese subjects
with type 2 diabetes (21), is a condition
frequently associated with the nondip-
ping pattern (22).
Whatever its mechanisms might be, a
ﬂattening and, even more importantly, an
inversion of day-night BP proﬁle (reverse
dipping) was demonstrated to be a
marker of complications in the diabetic
population (17). In particular, its associ-
ation with renal damage reﬂected by uri-
nary protein excretion is evident both in
type 1 (23) and type 2 (24) diabetes. The
results of some studies suggest that in
subjects with type 1 diabetes, elevated
systolic BP during sleep precedes the de-
velopment of microalbuminuria. Such an
alteration in nocturnal BP, therefore,
should be viewed as a cause (or at least a
marker) of renal damage rather than its
consequence (25). More recently, similar
results were obtained also in type 2 dia-
betes (26). Nondipping in diabetic sub-
jects may also be associated with an
increased overall mortality, but evidence
is limited in this regard (27).
In the context of daytime and night-
time BP assessment by ABPM, one has to
consider the possibility that the absolute
values of nocturnal BP might be more rel-
evant from the prognostic point of view
than the relative reduction of day-night
BP excursion. This possibility has been
recently supported by the results of a
number of outcome studies in uncompli-
cated hypertensive subjects, and some
data in this direction have been collected
also in subjects with type 2 diabetes (28).
OVERALL BP VARIABILITY
AND MORNING BP SURGE—
Apart from day-night BP changes,
ABPM is able to provide information on
other features of BP variability that may
be of interest in diabetic subjects and
have clinical relevance. One of them is
Figure 1—Size of nocturnal BP fall (dipping) in children with diabetes (f) compared with
healthycontrolsubjects( ).DBP,diastolicBP;SBP,systolicBP.Reprintedwithpermissionfrom
Dost et al. (18).
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pressed as a standard deviation of aver-
age 24-h, daytime, or night-time BP
values. This parameter is frequently in-
creased in diabetic subjects, which may
beasignofderangedautonomiccontrol
of circulation and/or of an increased ar-
terial stiffness. This appears to be the
caseinpatientswithdiabeticautonomic
neuropathy (29), in particular, when
associated with arterial baroreﬂex im-
pairment (30,31), and may be an inde-
pendent predictor of cardiovascular
complications (32). Autonomic neu-
ropathy is also frequently associated
with postprandial hypotension, another
speciﬁc component of 24-h BP variabil-
ity,whichcanalsobedetectedbyABPM
(33).
Another important feature of 24-h BP
proﬁle is the behavior of BP in the morn-
ing. Both excessive morning BP surge
(i.e., the extent of BP increase when wak-
ing up in the morning) and morning hy-
pertension (high BP level in morning
hours) are associated with adverse prog-
nosis in nondiabetic subjects (3). Morn-
ing hypertension is common in diabetic
patients, and it was shown to predict the
progression rate of diabetic nephropathy
(34).Althoughinthestudiespublishedso
farindiabeticpatients,homeBPmonitor-
ing was applied for the assessment of
morning BP behavior, ABPM might be
even better in this regard, since it allows a
dynamic and more detailed evaluation of
BP in the morning hours.
ADDITIONAL PARAMETERS
DERIVED FROM 24-H
ABPM— Another advantage of ABPM
is that it allows to obtain dynamic infor-
mation over 24 h not only on systolic and
diastolic BP values, but also on some
other relevant parameters that can be di-
rectly obtained or calculated from ambu-
latory BP recordings. This technique
provides information on heart rate at the
time of BP measurements all over the
24 h, and a rough estimate of heart rate
variability may also be obtained by com-
puting the standard deviation of average
24-h,daytime,ornighttimeheartrateval-
ues. Although a reduced heart rate vari-
ability in continuous ECG recordings is a
wellestablishedindexofdiabeticneurop-
athy, only one study assessed heart rate
variability from ambulatory BP record-
ings in diabetic subjects. This study con-
ﬁrmed that the degree of heart rate
ﬂuctuations also when assessed discon-
tinuously over 24 h by means of inter-
mittent readings is reduced in this
population, especially at night (35).
Pulse pressure, i.e., the difference be-
tween systolic and diastolic BP, depends
on both stroke volume and arterial prop-
erties and, when increased, is largely con-
sidered a surrogate marker of stiffening of
arterialwalls.Resultsofseveralstudiesin-
dicate that 24-h pulse pressure may be an
independent predictor of vascular com-
plications of diabetes, more powerful
than the assessment of pulse pressure in
clinic measurements, although it is not
clear whether it provides relevant addi-
tional information on top of what is al-
ready offered by 24-h systolic BP (36)
(Fig. 2). In the context of noninvasive
methods for evaluating arterial proper-
ties, a new index has been recently pro-
posed, based on analysis of ABPM data,
known as ambulatory arterial stiffness in-
dex. This index consists of the dynamic
evaluation of the degree of parallelism in
systolic and diastolic BP changes and is
calculatedastheregressioncoefﬁcientbe-
tweenthechangesindiastolicandsystolic
BP over 24 h. It has been suggested that
ambulatory arterial stiffness index may
indirectly reﬂect the degree of arterial
stiffness, and some studies have demon-
strated a relationship of ambulatory arte-
rial stiffness index with cardiovascular
events and organ damage (37). The pre-
cise interpretation of its value as a speciﬁc
index of arterial stiffness is, however,
made difﬁcult by the evidence of a strong
correlation between ambulatory arterial
stiffness index and the degree of noctur-
nal BP fall (38), a parameter largely inde-
pendent from arterial wall properties.
ConsideringthatnocturnalBPfalliscom-
monly small or absent in diabetic sub-
jects, it is hardly surprising that
ambulatory arterial stiffness index scored
worse than 24-h pulse pressure in pre-
dictingtheprogressionofrenaldamagein
this population (39).
DIABETES AND
PREGNANCY— Pregnancy is a con-
ditionwheretheinterplaybetweendiabe-
tes and hypertension is of particular
Figure 2—The rates of occurrences of cardiovascular, cerebrovascular, and all events in diabetic subjects divided by quartile of the distribution of
mean 24-h pulse pressure and by age at entry (40 and 41–59 years). Reprinted with permission from Nakano et al. (36).
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adversely inﬂuence the pregnancy out-
comes. The role of ABPM in this setting is
not well established, however. On one
side, some studies suggest its possible
usefulness in monitoring pregnant
women and in the early identiﬁcation of
pregnancy-induced hypertension, espe-
cially when nocturnal BP is considered
(40). On the other side, according to
some authors, ABPM adds little informa-
tion to that already provided by mi-
croalbuminuria assessment as far as
prediction of preeclampsia is considered
(41).
ABPM IN THE ASSESSMENT
OF ANTIHYPERTENSIVE
TREATMENT— An extremely im-
portant application of ABPM in hyperten-
sion is related to its ability to evaluate the
changes in BP induced by antihyperten-
sive therapy with greater accuracy and in
a much more detailed fashion than clinic
BP measurements, offering information
on actual 24-h BP coverage by a given
antihypertensive regimen (3). Consider-
ing that adequate BP control is of utmost
importanceindiabeticsubjects,theabove
properties of ABPM make it an essential
tool to verify the appropriateness and ef-
ﬁcacy of antihypertensive treatment also
in this group. The key aspects related to
ABPMapplicationinthiscontextinclude
the following: the possibility to identify
subjects inappropriately categorized by
clinic BP as controlled (masked hyper-
tension) or uncontrolled (white-coat
hypertension); the ability of ABPM to as-
sess the impact of treatment on particu-
larly important periods within 24 h
(nighttime, morning); and the availability
ofABPM-basedindexesofadequatedura-
tion of antihypertensive effect (trough-to-
peak ratio) and of the smoothness of BP
reduction by treatment throughout 24 h
(smoothness index). In fact, the studies
making use of ABPM in diabetic subjects
to assess the effects of hypertension treat-
ment have provided some interesting in-
formation. In particular, evidence has
been obtained that newer oral antidia-
betic drugs used in type 2 diabetes (but
not the older ones), in particular the thia-
zolidinediones, may have a beneﬁcial ef-
fect on 24-h BP levels and may also
improve the day-night BP proﬁle in dia-
betic (42,43) subjects.
Some information is available also on
theinﬂuenceofcurrentlyusedantihyper-
tensive regimens on 24-h BP in diabetic
patients, including angiotensin receptor
antagonists (44) and ACE inhibitors
(45,46). These studies have conﬁrmed
the efﬁcacy of these compounds in terms
of overall 24-h BP lowering, with no sig-
niﬁcant impact on day-night BP proﬁle.
Information has also been obtained by
ABPM on the effects of lipophylic calci-
um-channel blockers on 24-h BP in dia-
betic patients. These drugs reduced
systolic BP variability, monitored on a
beat-by-beat basis over 24 h, in diabetic
patients with hypertension. This im-
provement in hemodynamic conditions
was associated with an improved auto-
nomic cardiac modulation, as quantiﬁed
by an increased cardiac baroreﬂex sensi-
tivity (47).
Importantly, the ability of ABPM to
provide more precise information on BP
control by treatment might translate into
a better clinical practice, through identi-
ﬁcation of subjects with white-coat hy-
pertension and masked hypertension and
by stimulating a more aggressive treat-
ment when this is necessary to achieve
therapeutic targets (48).
LIMITATIONS OF ABPM
USE IN DIABETES— Although the
usefulness of ABPM in diabetic subjects
can hardly be questioned, one also has to
consider a few limitations of this tech-
nique, which may be important when
ABPM is to be applied in a clinical setting
in the management of diabetic patients.
One of the main concerns when applying
oscillometric devices in clinical practice
(andcurrentABPMdevicesarealmostex-
clusively based on oscillometric measure-
ments) is that the algorithms for BP
determinationbythesetechniquesarenot
disclosed by manufacturers. Therefore,
the validity of each oscillometric device
should by individually checked by inde-
pendent studies following predeﬁned in-
ternational protocols. Unfortunately in
diabetic patients, the difference between
BPvaluesobtainedwiththereferenceaus-
cultatory measurement and with the os-
cillometric method is not necessarily the
same found in nondiabetic subjects (49).
Therefore, devices with demonstrated va-
lidity in standard protocols carried out in
nondiabetic subjects may not necessarily
turn out to be accurate in subjects with
diabetes, possibly because of the altered
arterial wall properties typical of such a
condition. Thus, ideally, validation stud-
ies on oscillometric devices to be used in
diabetic patients should be separately
performed in this population. Unfortu-
nately, whereas many ABPM devices have
been validated in a general hypertensive
population, similar studies are lacking in
the setting of diabetes. Nevertheless, con-
sidering the prognostic superiority of
ABPM over clinic BP measurement dem-
onstrated also in diabetic patients, the
possibility of a minor inconsistency be-
tweenauscultatorymeasurementsandos-
cillometric ABPM values, due to the
particular characteristics of these sub-
jects, should not be viewed as a major
obstacle in their clinical application.
An obstacle that is clearly more im-
portant from the practical point of view is
the high cost and limited availability of
ABPM systems in general practice. Still,
this situation is changing, with the costs
ofdevicesbecominglower,thenumberof
centers equipped with the devices in-
creasing, and the reimbursement policies
becoming more favorable. For the time
being, in most developed countries, an
access to ABPM for a high-risk patient,
such as one with diabetes, should no
longer pose a major difﬁculty, also in re-
lation to its reimbursement by health in-
surance bodies.
Finally, an important but still unre-
solvedissueisthedeﬁnitionofABPMcut-
offs for hypertension diagnosis and the
identiﬁcation of therapeutic targets in di-
abetic subjects. Such thresholds are fairly
well deﬁned for nondiabetic subjects at
low or intermediate risk. Based on the re-
sultsofoutcomestudies,itisbelievedthat
a clinic BP of 140/90 mmHg corresponds
to ambulatory BP levels of 125–130/80
mmHg for 24 h, 135/85 for daytime, and
120/70 for nighttime (1,2). Conversely,
no corresponding deﬁnitions are avail-
able when considering high-risk patients
such as those with diabetes. However,
given that in this population clinic BP
threshold for hypertension diagnosis and
treatment is currently set at values as low
as 130/80 mmHg, it should be expected
that also ABPM thresholds should be
lower by 5–10 mmHg compared with a
nondiabetic population. Given the non-
linearityoftherelationbetweenclinicand
ambulatory BP, however, ABPM thresh-
olds in diabetic patients need to be de-
ﬁned on the basis of future outcome
studies.
CONCLUSIONS:
INDICATIONS FOR ABPM
IN DIABETIC SUBJECTS — In sum-
mary, ABPM in diabetic subjects may be a
powerful tool for a better stratiﬁcation of
the cardiovascular risk related to elevated
BP, a condition that is one of the most
Parati and Bilo
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tality in this population. This is of partic-
ular importance also on the background
of the evidence that, in diabetic patients,
ofﬁce BP frequently fails to identify their
exposure to elevated BP in daily life con-
ditions. Moreover, ABPM may also be
helpful in detecting alterations in auto-
nomic control of the cardiovascular sys-
tem,reﬂectedbytheabsenceofnocturnal
BP fall, by postprandial hypotension, or
by a reduced 24-h heart rate variability
and an increased 24-h BP variability.
Thus, theoretically, a noninvasive and
powerful test such as ABPM could be use-
ful in every diabetic subject.
However, given the limited availabil-
ity of ABPM in daily practice and the pro-
gressive increase in the number of
diabetic subjects, it is reasonable to sug-
gestanindividualizedapproachwhende-
ﬁning indications to ABPM performance
in such a population. As a general princi-
ple, ABPM should be applied in those
cases where the largest beneﬁts can be ex-
pected. In practice, the pros and cons of
performingABPMshouldbeevaluatedon
acase-by-casebasis,takingintoconsider-
ation a number of key factors, such as the
likelihoodofmisdiagnosingactualBPlev-
els by ofﬁce BP, the possible beneﬁts as-
sociated with a more accurate estimation
of 2-h BP levels and variability (as in pa-
tients with previous clinical events, such
as stroke, myocardial infarction, or im-
paired renal function), the probability of
nocturnal hypertension, and the avail-
ability of alternative (and cheaper) solu-
tions for out-of-ofﬁce BP measurement,
such as home BP monitoring.
Based on the above considerations, a
fewrecommendationscanbeproposedto
identify the possible situations in which
ABPM might be indicated in hypertensive
subjectswithdiabetes.Onesuchpossibil-
ity is the ﬁnding of clinic BP values close
to the threshold levels. This is because
these patients are most likely to have
white-coat hypertension (if ofﬁce BP is
slightly above the threshold) or masked
hypertension (when it is slightly below).
In such a case, however, home BP moni-
toring may be an easier, cheaper, and
equally effective (50) way to determine
the true status of patients’ BP under daily
life conditions. When home BP monitor-
ing is not feasible, or its results are not
easy to interpret (borderline values, high
variability), ABPM should then be per-
formed. Another example of subjects in
whom a suspicion of imprecise diagnosis
by ofﬁce BP should be considered are
those with signs of organ damage despite
apparently normal BP in the physician’s
ofﬁce or in the clinic (in diabetic subjects,
it is much less likely that the opposite sit-
uation is encountered). This may imply
that BP is elevated only in their daily life,
a condition that needs out-of-ofﬁce BP
monitoring to be identiﬁed. Needless to
say,suchdiabeticpatients,beingexposed
at a very high risk, may derive particular
beneﬁtfromanappropriatediagnosisand
an effective treatment of their daily life
hypertension.
ABPM may also be of particular im-
portance in subjects already under anti-
hypertensive treatment. Even though
homeBPmonitoringmaybesufﬁcientfor
a long-term follow-up, ABPM is the only
waytoascertainthatBPisadequatelycon-
trolledalloverthe24-hperiodandinpar-
ticular during the night. Nocturnal
hypertension should be suspected specif-
icallyinsubjectslikelytohaveobstructive
sleep apneas (obese subjects, snoring his-
tory, daytime somnolence), in those with
autonomicdysfunction,andinthosewith
organ damage, especially when kidneys
are affected (microalbuminuria or overt
proteinuria, signs of renal failure). In
these cases, some simple measures, such
asswitchingtolong-actingcompoundsor
adding an evening dose of antihyperten-
sive drugs, may be effective. However, it
should be emphasized in this context that
the occurrence of clinical beneﬁts from
restoringanormalday-nightBPrhythmis
only assumed and has not yet been di-
rectlydemonstrated.ABPMmayalsohelp
to identify subjects with episodic BP
drops (as in the case of postprandial hy-
potension related to autonomic dysfunc-
tion) and should be performed if patient
reports typical hypotensive symptoms
that have not been otherwise clariﬁed.
Also in such cases, the adjustment of an-
tihypertensive treatment or advice on
changes in lifestyle may be effective and
improve the subject’s quality of life. Fi-
nally, ABPM may also be useful when
identifying patients with episodic BP ele-
vations, in the context of an enhanced BP
variability,increasedarterialstiffness,and
autonomic neuropathy. The identiﬁca-
tion of these phenomena may trigger ap-
propriate changes in treatment strategies,
too, given the prognostic relevance of
these ﬁndings.
In spite of its advantages, ABPM may
not be easily applied in every diabetic
subject, both for technical and ﬁnancial
reasons. However, it is important to em-
phasize that, when appropriately used,
this approach may be an extremely useful
tool in improving outcome and quality of
life of these subjects and therefore should
become an integral part of the clinical
management, at least in a subgroup of se-
lected diabetic patients.
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